Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 878 participants.

Also called NCT03798054

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 878 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03798054
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Malaysia, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03798054. Randomized; no masking; primary purpose treatment. Start 2019-02-15 (actual); primary completion 2021-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Acronym
Lixilan-O-AP
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Intervention (Drug)
Insulin glargine (HOE901)
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Metformin
Intervention (Drug)
SGLT2 inhibitor
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03798054
Content hash
96b17a7b3530e8ace7b5948fc8259770402cb8465d1e94e73ba2f7932aca1774